F. Hoffmann-La Roche AG
F. Hoffmann-La Roche AG, commonly known as Roche, is a leading global healthcare company headquartered in Basel, Switzerland (CH). Founded in 1896, Roche has established itself as a pioneer in the pharmaceutical and diagnostics industries, focusing on innovative solutions for oncology, immunology, infectious diseases, and personalised medicine. With a strong presence in Europe, North America, and Asia, Roche is renowned for its commitment to research and development, boasting a robust portfolio of core products, including groundbreaking biologics and diagnostic tools. The company’s unique approach to integrating pharmaceuticals and diagnostics sets it apart in the market, enabling tailored treatment options for patients. Roche's notable achievements include being consistently ranked among the top pharmaceutical companies worldwide, reflecting its dedication to advancing healthcare and improving patient outcomes.
DitchCarbon Score
How does F. Hoffmann-La Roche AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
F. Hoffmann-La Roche AG's score of 50 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
F. Hoffmann-La Roche AG's reported carbon emissions
F. Hoffmann-La Roche AG, headquartered in Switzerland (CH), currently does not have publicly available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in the available information. In the absence of specific emissions data, it is important to note that many companies in the pharmaceutical industry are increasingly focusing on sustainability and climate commitments. This often includes initiatives aimed at reducing greenhouse gas emissions across all scopes—Scope 1 (direct emissions), Scope 2 (indirect emissions from energy), and Scope 3 (indirect emissions from the supply chain). As the industry evolves, F. Hoffmann-La Roche AG may align with global standards and frameworks, such as the Science Based Targets initiative (SBTi), to establish meaningful climate commitments in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
F. Hoffmann-La Roche AG is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
